BDKRB2 and angioedema: In Germany, current treatment options approved for therapy of acute angioedema in HAE-Type I and II patients comprise intravenous replacement therapy with a pasteurized pd C1-INH concentrate and subcutaneous injection of the bradykinin B2-receptor antagonist Icatibant.